mt-2990
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 17, 2017 (NCT03156738)
Timeline
Indications
Mechanism of action
- Interleukin-33INHIBITOR
IL33 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mt-2990
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06196905 | Phase 1 | Jun 24, 2024 | Mitsubishi Tanabe |
| NCT03840993 | Phase 2 | Jan 15, 2019 | Mitsubishi Tanabe |
| NCT03570957 | Phase 1 | Jul 17, 2018 | Mitsubishi Tanabe |
| NCT03156738 | Phase 1 | May 17, 2017 | Mitsubishi Tanabe |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mitsubishi Tanabe | For profit | 4 | 4 | 2 | 2017 |
1 organizations
Page 1 / 1